**Name of Journal:** *World Journal of Virology*

**Manuscript NO:** 68481

**Manuscript Type:** LETTER TO THE EDITOR

**Repurposing the antioxidant and anti-inflammatory agent N-acetyl cysteine for treating COVID-19**

Finsterer J *et al*. N-acetyl-cysteine for COVID-19

Josef Finsterer, Fulvio A Scorza, Carla A Scorza, Ana C Fiorini

**Josef Finsterer,** Neurological Department, Messerli Institute, Vienna 1180, Austria

**Fulvio A Scorza, Carla A Scorza, Ana C Fiorini,** Department of Neurology, University of Sao Paolo, Sao Paolo 01000-000, Brazil

**Author contributions:** Finsterer J contributed todesign, first draft, literature search, discussion, final approval; Scorza FA, Scorza CA, and Fiorini AC contributed to the literature search, discussion, final approval.

**Corresponding author: Josef Finsterer, MD, Lecturer,** Neurological Department, Messerli Institute, Postfach 20, Vienna 1180, Austria. fifigs1@yahoo.de

**Received:** May 24, 2021

**Revised:** June 23, 2021

**Accepted:** December 10, 2021

**Published online:** January 25, 2022

**Abstract**

Although several considerations have been raised suggesting a beneficial effect of N-acetyl cysteine (NAC) for the treatment of severe acute respiratory syndrome coronavirus 2 infection, there is currently no clinical evidence that NAC truly prevents coronavirus disease 2019 (COVID-19), reduces the severity of the disease, or improves the outcome. Appropriately designed clinical trials are warranted to prove or disprove a therapeutic effect of NAC for COVID-19 patients.

**Key Words:** N-acetyl cysteine; SARS-CoV-2; COVID-19; reactive oxygen species; cytokines

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Finsterer J, Scorza FA, Scorza CA, Fiorini AC. Repurposing the antioxidant and anti-inflammatory agent N-acetyl cysteine for treating COVID-19. *World J Virol* 2022; 11(1): 82-84

**URL:** <https://www.wjgnet.com/2220-3249/full/v11/i1/82.htm>

**DOI:** https://dx.doi.org/10.5501/wjv.v11.i1.82

**Core tip:** N-acetyl cysteine (NAC) is a well-known antioxidant and anti-inflammatory agent that has been considered beneficial in the treatment for coronavirus disease 2019 (COVID-19). Although previous studies in patients with chronic lung disease, chronic heart disease, immune-mediated disease, viral infections, and malignancy have shown promising results, there is currently no clinical evidence that NAC prevents COVID-19, alleviates the severity of COVID-19, or improves the overall outcome of COVID-19 patients.

**TO THE EDITOR**

With interest, we read the review article by Dominari *et al*[1] about the putative therapeutic effect of N-acetyl cysteine (NAC) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients. The authors raise several arguments in favour of a beneficial effect of NAC for coronavirus disease 2019 (COVID-19), discuss preliminary results about ongoing studies with NAC in COVID-19, and conclude that the results of available trials are not clear. The study is appealing but raises the following comments and concerns.

We do not agree with the notion that NAC is an agent for curing SARS-CoV-2 infections[1]. There are several arguments against the antiviral effect of NAC. First, NAC is primarily an antioxidant and a precursor of reduced glutathione (GSH) that replenishes GSH stores[2]. NAC reduces oxidative stress as it scavenges and neutralises reactive oxidative species, such as OH, HOCl, or RO2[3]. Thus, NAC is approved as a preventive/therapeutic agent in disorders associated with GSH depletion, as an antidote in paracetamol intoxication, and as a mucolytic agent[2]. Since SARS-CoV-2 infections are associated with oxidative stress, NAC can, at best, reduce oxidative stress and thus reduce secondary effects of the infection[2]. Although NAC additionally has an anti-inflammatory effect by reducing cytokine production *via* blocking of matrix metalloproteinase (MMP)-1, MMP-4, intracellular adhesion molecule 1, nuclear factor κB, NF-E2-related factor 2, and tryparedoxin-1b[2], NAC cannot neutralise the virus and cannot reduce the virus load. Thus, NAC may have, at best, a complementary but no curative effect in SARS-CoV-2 infections as all infections are associated with increased oxidative stress and cytokine activation. Second, there are no reports that NAC is capable of reducing viral load, preventing infection, alleviating severity of COVID-19, or reducing mortality. Third, many patients are regularly taking NAC for the treatment of bronchitis, bronchiolitis, pneumonia, asthma, or chronic obstructive pulmonary disease. However, there are no indications that patients regularly taking NAC have a decreased risk of SARS-CoV-2 infection, or that morbidity or mortality of SARS-CoV-2 infection in these patients is lower compared with that in patients not taking NAC. Fourth, NAC did not prevent the presence of SARS-CoV-2 in sputum[4]. Arguments in favour of a promising role of NAC in the management of COVID-19, however, are that it generally enhances immunocompetence[5] and that it inhibits the replication of the influenza virus H5N1[6]. A potential beneficial effect of NAC for treating COVID-19 may also derive from its capacity to increase glutathione, improve T-cell responses, and modulate inflammation[7-12]. Currently, a protocol for using NAC together with heparin has been developed[13] but no results have yet been published. Since several studies concerning the role of NAC in COVID-19 are under way, final conclusions about its contribution for treating COVID-19 cannot be reliably drawn. Future studies may demonstrate that NAC can reduce replication of SARS-CoV-2. Overall, agents that appear beneficial theoretically need to be thoroughly investigated by appropriately designed clinical trials for their putative beneficial effect. This is particularly the case for anti-COVID-19 agents, as there is strong pressure from healthcare authorities, industry, and the global community to provide a safe and effective cure of this global threat that currently influences all segments of social, economic, scientific, and political life. Effective and safe agents are needed as several drugs that were proposed to be beneficial at the beginning of the pandemic turned out to be harmful or inefficient, such as chloroquine, azithromycin and tocilizumab.

**REFERENCES**

1 **Dominari A**, Hathaway Iii D, Kapasi A, Paul T, Makkar SS, Castaneda V, Gara S, Singh BM, Agadi K, Butt M, Retnakumar V, Chittajallu S, Taugir R, Sana MK, Kc M, Razzack S, Moallem N, Alvarez A, Talalaev M. Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19. *World J Virol* 2021; **10**: 34-52 [PMID: 33816149 DOI: 10.5501/wjv.v10.i2.34]

2 **De Flora S**, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. *FASEB J* 2020; **34**: 13185-13193 [PMID: 32780893 DOI: 10.1096/fj.202001807]

3 **Mohanty RR**, Padhy BM, Das S, Meher BR. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence. *Eur Rev Med Pharmacol Sci* 2021; **25**: 2802-2807 [PMID: 33829465 DOI: 10.26355/eurrev\_202103\_25442]

4 **Peng J**, Lu Y, Song J, Vallance BA, Jacobson K, Yu HB, Sun Z. Direct Clinical Evidence Recommending the Use of Proteinase K or Dithiothreitol to Pretreat Sputum for Detection of SARS-CoV-2. *Front Med (Lausanne)* 2020; **7**: 549860 [PMID: 33043036 DOI: 10.3389/fmed.2020.549860]

5 **Meletis CD**, Wilkes K. Immune Competence and Minimizing Susceptibility to COVID-19 and Other Immune System Threats. *Altern Ther Health Med* 2020; **26**: 94-99 [PMID: 33245701]

6 **Geiler J**, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, Cinatl J Jr. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. *Biochem Pharmacol* 2010; **79**: 413-420 [PMID: 19732754 DOI: 10.1016/j.bcp.2009.08.025]

7 **Radtke KK**, Coles LD, Mishra U, Orchard PJ, Holmay M, Cloyd JC. Interaction of N-acetylcysteine and cysteine in human plasma. *J Pharm Sci* 2012; **101**: 4653-4659 [PMID: 23018672 DOI: 10.1002/jps.23325]

8 **Scheffel MJ**, Scurti G, Wyatt MM, Garrett-Mayer E, Paulos CM, Nishimura MI, Voelkel-Johnson C. N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner. *Cancer Immunol Immunother* 2018; **67**: 691-702 [PMID: 29396710 DOI: 10.1007/s00262-018-2120-5]

9 **Malorni W**, Rivabene R, Lucia BM, Ferrara R, Mazzone AM, Cauda R, Paganelli R. The role of oxidative imbalance in progression to AIDS: effect of the thiol supplier N-acetylcysteine. *AIDS Res Hum Retroviruses* 1998; **14**: 1589-1596 [PMID: 9840292 DOI: 10.1089/aid.1998.14.1589]

10 **De Rosa SC**, Zaretsky MD, Dubs JG, Roederer M, Anderson M, Green A, Mitra D, Watanabe N, Nakamura H, Tjioe I, Deresinski SC, Moore WA, Ela SW, Parks D, Herzenberg LA, Herzenberg LA. N-acetylcysteine replenishes glutathione in HIV infection. *Eur J Clin Invest* 2000; **30**: 915-929 [PMID: 11029607 DOI: 10.1046/j.1365-2362.2000.00736.x]

11 **Liu Y**, Yao W, Xu J, Qiu Y, Cao F, Li S, Yang S, Yang H, Wu Z, Hou Y. The anti-inflammatory effects of acetaminophen and N-acetylcysteine through suppression of the NLRP3 inflammasome pathway in LPS-challenged piglet mononuclear phagocytes. *Innate Immun* 2015; **21**: 587-597 [PMID: 25575547 DOI: 10.1177/1753425914566205]

12 **Lee SI**, Kang KS. N-acetylcysteine modulates lipopolysaccharide-induced intestinal dysfunction. *Sci Rep* 2019; **9**: 1004 [PMID: 30700808 DOI: 10.1038/s41598-018-37296-x]

13 **Poe FL**, Corn J. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. *Med Hypotheses* 2020; **143**: 109862 [PMID: 32504923 DOI: 10.1016/j.mehy.2020.109862]

**Footnotes**

**Conflict-of-interest statement:** None of the authors have any conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** May 24, 2021

**First decision:** June 17, 2021

**Article in press:** December 10, 2021

**Specialty type:** Neurosciences

**Country/Territory of origin:** Austria

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Arumugam VA, Ratajewski M, Tantau AI **S-Editor:** Gong ZM **L-Editor:** Kerr C **P-Editor:** Gong ZM



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**